Thrivent Financial for Lutherans Lowers Position in IQVIA Holdings Inc. $IQV

Thrivent Financial for Lutherans trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 21.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 30,307 shares of the medical research company’s stock after selling 8,051 shares during the quarter. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $5,757,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Independent Advisor Alliance raised its holdings in IQVIA by 12.6% during the third quarter. Independent Advisor Alliance now owns 1,874 shares of the medical research company’s stock valued at $356,000 after acquiring an additional 210 shares during the period. Keybank National Association OH increased its stake in IQVIA by 3.4% in the 3rd quarter. Keybank National Association OH now owns 9,036 shares of the medical research company’s stock worth $1,716,000 after acquiring an additional 297 shares during the last quarter. Howard Capital Management Inc. bought a new stake in IQVIA in the third quarter worth $219,000. National Pension Service increased its holdings in shares of IQVIA by 2.8% in the 3rd quarter. National Pension Service now owns 287,089 shares of the medical research company’s stock worth $54,530,000 after buying an additional 7,903 shares during the last quarter. Finally, Twin City Private Wealth LLC raised its position in IQVIA by 13.9% during the third quarter. Twin City Private Wealth LLC now owns 10,188 shares of the medical research company’s stock valued at $1,935,000 after purchasing an additional 1,242 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IQV shares. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a research report on Friday. TD Cowen upped their price target on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Mizuho set a $266.00 target price on IQVIA in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Finally, Robert W. Baird set a $258.00 price target on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.75.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Trading Up 3.6%

IQVIA stock opened at $187.50 on Friday. The stock has a 50-day moving average of $228.03 and a two-hundred day moving average of $209.61. The stock has a market cap of $31.93 billion, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.84 and a beta of 1.37. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the previous year, the firm earned $3.12 EPS. IQVIA’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.